FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with BREAKING: The FDA just made it official. Advisory committee meetings are now scheduled for July 23 24 to review reclassifying peptides back to legal compounding status. Here's what's happening: After the Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law